

Supplemental Table S1. Recombinant proteins of mouse 5G culture medium [8].

recombinant proteins	company, catalog No.	concentration
mouse SCF	Peprotech, 250-03	100 ng/ml
mouse Flt-3 ligand	Peprotech, 250-31L	100 ng/ml
mouse TPO	Peprotech, 315-14	20 ng/ml
mouse VEGF	Peprotech, 450-32	50 ng/ml
mouse IL-6	Peprotech, 216-16	20 ng/ml

Supplemental Table S2-1. Mouse antibodies for flow cytometric analysis.

antibodies	company, catalog No.
APC-Cy7 anti-mouse/human CD11b	Biolegend, 101225
APC/Cy7 Rat IgG2b, κ isotype Ctrl Antibody	Biolegend, 400623
APC anti-mouse CD206 (MMR)	Biolegend, 141707
APC Rat IgG2a, κ Isotype Ctrl Antibody	Biolegend, 400511
PE anti-mouse CD3	Biolegend, 100205
PE Rat IgG2b, κ isotype Ctrl Antibody	Biolegend, 400607
APC-Cy7 anti-mouse CD4	Biolegend, 100413
APC-Cy7 Rat IgG2b, κ isotype Ctrl Antibody	Biolegend, 400623
FITC anti-mouse/human CD45R/B220	Biolegend, 103205
FITC Rat IgG2a, κ isotype Ctrl Antibody	Biolegend, 400505
APC anti-mouse CCR2	R&D, FAB5538A
APC Rat IgG2b, κ isotype Ctrl Antibody	Biolegend, 400611
FITC anti-mouse Msr1(CD204)	BIO-RAD, MCA1322FT
FITC Rat IgG2b, κ isotype Ctrl Antibody	BD, 553988
FITC anti-mouse CD183 (CXCR3)	Biolegend, 126535
FITC Armenian hamster IgG, isotype Ctrl Antibody	Biolegend, 400905
PE/Cy7 anti-mouse CD194 (CXCR4)	Biolegend, 131213
PE/Cy7 Armenian hamster IgG, isotype Ctrl Antibody	Biolegend, 400921
APC anti-mouse CD196 (CCR6)	Biolegend, 129813
APC Armenian hamster IgG, isotype Ctrl Antibody	Biolegend, 400911
PE-Cy7 anti-mouse/human Mac-2 (Galectin-3)	Biolegend, 125417
PE-Cy7 Rat IgG2a, κ isotype Ctrl Antibody	Biolegend, 400521
True-Stain Monocyte Blocker™	Biolegend, 426102
PI	WAKO, 169-26281

Supplemental Table S2-2. Human antibodies for flow cytometric analysis.


antibodies	company, catalog No.
PE-Cy7 mouse IgG1, κ isotype Ctrl Antibody	Biolegend, 400126
PE-Cy7 anti-human CD11b	Biolegend, 301322
APC-Cy7 mouse IgG1, κ isotype Ctrl Antibody	Biolegend, 400128
APC-Cy7 anti-human CD206	Biolegend, 321120
FcR Blocking Reagent, human	Miltenyi Biotec, 130-059-901
PI	WAKO, 169-26281

Supplemental Table S3-1. Mouse primers.

gene	forward	reverse
IL-1 β	5'-GCTGAAAGCTCTCCACCTCA-3'	5'-AGGCCACAGGTATTTGTCG-3'
IL-10	5'-GCTGGACAACATACTGCTAAC-3'	5'-ATTCCGATAAGGCTTGGCAA-3'
IFN- γ	5'-ACAGCAAGGCAGAAAAGGATG-3'	5'-TGGTGGACCACCTCGGATGA-3'
VEGF-A	5'-CCTCCGAAACCATGAACCTT-3'	5'-TCATGGACTCTGCTCTCC-3'
IL-6	5'-CCACTCCCACAGACCTGTC-3'	5'-GCAAGTGCATCATCGTTGTC-3'
CD206	5'-CCACAGCATTGAGGAGTTG-3'	5'-ACAGCTCATCATTGGCTCA-3'
IGF1	5'-CACACCTCTTCTACCTGGCG-3'	5'-AGCCTGTGGCTTGTGAAG-3'
TGF- β	5'-GGACTCTCCACCTGCAAGAC-3'	5'-GACTGGCGAGCCTTAGTTG-3'
TLR2	5'-AACTCTGACCCGCCCTTAA-3'	5'-AGCCTGAAGTGGAGAAGTC-3'
TLR4	5'-CTGCATAGAGGTAGTCCTA-3'	5'-AATTCACACCTGGATAAAAT-3'
NGF	5'-ATGGGGGAGTTCTCAGTGTG-3'	5'-GCACCCACTCTCAACAGGAT-3'
Car3	5'-CTTGATGCCCTGGACAAAAT-3'	5'-AGCTCACAGTCATGGCTCT-3'
MMP9	5'-CGTCATTGGCGTGGATAAGG-3'	5'-TTTGGAAACTCACACGCCAG-3'
GAPDH	5'-TGCACCACCAACTGCTTAG-3'	5'-GGATGCAGGGATGATGTTGTC-3'

Supplemental Table S3-2. Human primers.


gene	forward	reverse
IL-1 β	5'-CACAGACCTTCCAGGAGAAT-3'	5'-TTCAACACGCAGGACAGGTA-3'
TNF- α	5'-AATGGCGTGGAGCTGAGA-3'	5'-TAGACCTGCCAGACTCGG-3'
IFN- γ	5'-CTGTTACTGCCAGGACCCAT-3'	5'-ACACTCTTTGGATGCTCTGGT-3'
GAPDH	5'-GGAGTCCACTGGCGTCTCAC-3'	5'-GCTGATGATCTGAGGCTGTTGTC-3'




Supplemental Figure S1. Schematic diagram describing the experimental design for co-culture of E-MNCs and T-cell–activated PBMNCs. Anti-CD3 and -CD28 antibodies were added to the wells of a 24-well plate and incubated overnight. Then, PBMNCs were seeded to the wells and cultured at 37°C for 1 h. Subsequently, E-MNCs, 11b(–) cells, or 11b(+) cells were seeded to the upper chamber and co-cultured with stimulated PBMNCs at 37°C for 1 h. Finally, co-cultured PBMNCs were collected and analyzed.

A.

PBMNC (day 0)




E-MNC (day 7)




Supplemental Figure S2. Characteristics of human E-MNCs. (A) Phase-contrast imaging of PBMNCs (day 0) and E-MNCs (day 7). White arrows indicate round- and spindle-shaped macrophage-like cells (white arrows). Scale bar; 200 μ m.

A.




Supplemental Figure S3. Characteristics of human E-MNCs. **(A)** Phagocytosis assay with fluorescent beads. Phase-contrast and fluorescence microscopic images of macrophage-like round- and spindle-shaped cells (black arrows) among E-MNCs at 1 h. Green, fluorescent beads; Blue, DAPI. Scale bar 100 μ m.

A.





Supplemental Figure S4. Microarray analysis of PBMNCs and E-MNCs. (A) Heat map showing down-regulated and up-regulated genes associated with inflammation, matrix metalloproteases, angiogenesis, tissue regeneration, and M2-macrophages in PBMNCs (day 0) and E-MNCs (day 5). Red color indicates relatively higher expression, and green color indicates relatively lower expression.

A.




Supplemental Figure S5. Changes in body weight in the prevention mouse model after transplantation. **(A)** Change in body weight in each group at 1, 2, 5, 9, and 13 weeks post-IR (upper graph) and scatter diagram of body weight in each specimen at 5, 9, and 13 weeks post-IR (lower graphs) (* $P<0.05$, ** $P<0.01$).

A.**B.**


Supplemental Figure S6. Microarray and qPCR analyses of transplanted specimens at 2 weeks post-IR. **(A)** Heat map showing down-regulated and up-regulated genes associated with inflammation, matrix metalloproteases, apoptosis, angiogenesis, tissue regeneration, and M2-macrophages in the IR- and E-MNC-groups. Red color indicates relatively higher expression, and green color indicates relatively lower expression. **(B)** Expression of mRNAs of genes encoding MMP9, NGF, and Car3 in each group (*P<0.05, **P<0.01).

A.



B.

damage-established model



Supplemental Figure S7. Immunohistological observations at 10 days post-IR and changes in body weight after transplantation. (A) CD206-expressing cells (red) at the periphery of transplanted E-MNCs (green). Blue, DAPI. Scale bar, 50 μ m. (B) Changes in body weight in each group of the established model at 2, 5, 9, and 13 weeks post-IR (upper graph), and scatter diagram of body weight in each specimen at 9 and 13 weeks post-IR (lower graphs) (*P<0.05, **P<0.01).